Search our database and find Biotech companies in Botswana based on your preferred criteria. Get key company details, track changes, and gain actionable insights to drive business growth or investment decisions.
Get to know our data at a glance with this sample company profile. We cover everything you need to know about Botswana Biotech companies.
Available data points
Metadata
company_id
9238086
source_id
793445
unique_domain
1
unique_website
1
last_updated_at
2025-04-04
created_at
2016-06-25
description
Affimed N.V. (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s Innate Cell Engagers (ICE®), generated from its proprietary ROCK® platform, are bispecific antibodies, which target innate immune cells, e.g. natural killer (NK) cells and macrophages, to destroy tumor cells. Affimed’s ICE® enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors with activity demonstrated as monotherapy and when given in combination with NK cells and other I-O therapeutics. Affimed has three active clinical programs focused on solid tumors and blood cancers. The lead candidate Acimtamig (AFM13) is in development for patients with CD30-positive lymphomas. Acimtamig combined with NK cells has demonstrated high objective response rates in heavily pretreated, relapsed / refractory (r/r) Hodkin lymphoma (HL) patients with a manageable safety profile in a clinical trial (AFM13-104). Affimed’s phase 2 study, LuminICE-203, is underway to investigate acimtamig in combination with AlloNK® (also known as AB-101), an off-the-shelf, allogeneic NK cell from Artiva Biotherapeutics, in patients with r/r HL with an exploratory arm planned in patients with r/r/ peripheral T-cell lymphoma (PTCL). AFM24 is in development for epidermal growth factor receptor (EGFR)-expressing solid tumors. Based on the data generated to date, the developmental focus of AFM24 is in combination with the anti-PD-L1 inhibitor atezolizumab in advanced stage EGFR-positive non-small cell lung cancer (NSCLC). AFM28 is being developed for patients with CD123-expressing acute myeloid leukemia (AML) in need of new therapeutic options. A first-in-human Phase 1 clinical study is underway (AFM28-101) and development in combination with allogeneic NK cell therapy is being explored.
type
Public Company
industry_group_1
Biotech
Firmographics
company_name
Affimed
company_legal_name
Affimed GmbH
industry
Biotechnology Research
founded_year
2000
size_range
51-200 employees
employees_count
88
Locations
hq_country
Botswana
hq_country_iso2
BW
hq_country_iso3
BWA
hq_location
Mannheim, BW, Botswana
hq_full_address
*******
Follower counts & changes
followers_count_professional_network
6827
followers_count_owler
97
Financials
is_public
1
ipo_date
2014-09-12
ipo_share_price
7
ipo_share_price_currency
USD
Funding
last_funding_round_name
Post-IPO Equity - Affimed
last_funding_round_announced_date
2022-04-13
last_funding_round_amount_raised
90000000
last_funding_round_amount_raised_currency
$
Technographics
num_technologies_used
5
Company websites and social media
website
https://www.affimed.com
professional_network_url
https://www.professional-network.com/company/affimed-ag
financial_website_url
https://www.financial-website.com/organization/affimed-therapeutics
JSON data sample
{ "company_id": 9238086, "source_id": "793445", "company_name": "Affimed", "company_name_alias": [ "affimed", "affimed n.v.", "affimed gmbh" ], "company_legal_name": "Affimed GmbH", "company_logo": "/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAMCAgMCAgMDAwMEAwMEBQgFBQQEBQoHBwYIDAoMDAsK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\r\noooAKKKKACiiigAooooAKKKKACiiigD/2Q==", "website": "https://www.affimed.com", "professional_network_url": "https://www.professional-network.com/company/affimed-ag", "twitter_url": [ "https://www.twitter.com/affimed?lang=en", "https://www.twitter.com/affimed" ], "discord_url": [], "facebook_url": [], "instagram_url": [], "pinterest_url": [], "tiktok_url": [], "youtube_url": [], "github_url": [], "reddit_url": [], "financial_website_url": "https://www.financial-website.com/organization/affimed-therapeutics", "stock_ticker": [ { "exchange": null, "ticker": "AFMD" }, { "exchange": "NASDAQ", "ticker": "AFMD" } ], "is_b2b": 0, "industry": "Biotechnology Research", "sic_codes": [ "28", "283" ], "naics_codes": [ "32", "325" ], "categories_and_keywords": [ "healthcare", "tumor destruction", "cancer treatment", "revolutionary outcomes", "innate immunity", "tumors", "health", "clinics", "pharma", "biotechnology", "clinical trials", "health care", "medical", "therapeutics" ], "description": "Affimed N.V. (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s Innate Cell Engagers (ICE®), generated from its proprietary ROCK® platform, are bispecific antibodies, which target innate immune cells, e.g. natural killer (NK) cells and macrophages, to destroy tumor cells. Affimed’s ICE® enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors with activity demonstrated as monotherapy and when given in combination with NK cells and other I-O therapeutics. Affimed has three active clinical programs focused on solid tumors and blood cancers. The lead candidate Acimtamig (AFM13) is in development for patients with CD30-positive lymphomas. Acimtamig combined with NK cells has demonstrated high objective response rates in heavily pretreated, relapsed / refractory (r/r) Hodkin lymphoma (HL) patients with a manageable safety profile in a clinical trial (AFM13-104). Affimed’s phase 2 study, LuminICE-203, is underway to investigate acimtamig in combination with AlloNK® (also known as AB-101), an off-the-shelf, allogeneic NK cell from Artiva Biotherapeutics, in patients with r/r HL with an exploratory arm planned in patients with r/r/ peripheral T-cell lymphoma (PTCL). AFM24 is in development for epidermal growth factor receptor (EGFR)-expressing solid tumors. Based on the data generated to date, the developmental focus of AFM24 is in combination with the anti-PD-L1 inhibitor atezolizumab in advanced stage EGFR-positive non-small cell lung cancer (NSCLC). AFM28 is being developed for patients with CD123-expressing acute myeloid leukemia (AML) in need of new therapeutic options. A first-in-human Phase 1 clinical study is underway (AFM28-101) and development in combination with allogeneic NK cell therapy is being explored.", "description_enriched": "Affimed is a company pioneering a transformative innate immunity therapeutic approach to eradicating solid and hematologic tumors to help patients fight cancer.", "description_metadata_raw": "Affimed (AFMD) is pioneering a transformative innate immunity therapeutic approach to eradicating solid and hematologic tumors to help patients fight cancer.", "type": "Public Company", "status": { "value": "active", "comment": "Independent Company" }, "founded_year": "2000", "size_range": "51-200 employees", "employees_count": 88, "followers_count_professional_network": 6827, "followers_count_twitter": null, "followers_count_owler": 97, "hq_region": [ "Africa", "Sub-Saharan Africa", "Southern Africa", "EMEA" ], "hq_country": "Botswana", "hq_country_iso2": "BW", "hq_country_iso3": "BWA", "hq_location": "Mannheim, BW, Botswana", "hq_full_address": "*******", "hq_city": null, "hq_state": null, "hq_street": null, "hq_zipcode": null, "company_locations_full": [ { "location_address": "*******", "is_primary": 1 }, { "location_address": "*******", "is_primary": 0 }, { "location_address": "*******", "is_primary": 0 }, { "location_address": "*******", "is_primary": 0 }, { "location_address": "*******", "is_primary": 0 } ], "is_public": 1, "ipo_date": "2014-09-12", "ipo_share_price": 7, "ipo_share_price_currency": "USD", "revenue_annual_range": null, "revenue_annual": { "source_5_annual_revenue": { "annual_revenue": 12894138, "annual_revenue_currency": "$" }, "source_1_annual_revenue": { "annual_revenue": 8275000, "annual_revenue_currency": "€" } }, "revenue_quarterly": { "value": 155000, "currency": "€" }, "income_statements": [ { "cost_of_goods_sold": 0, "cost_of_goods_sold_currency": "€", "ebit": -7913000, "ebitda": -7814000, "ebitda_margin": -14.68796992481203, "ebit_margin": -14.87406015037594, "earnings_per_share": null, "gross_profit": 532000, "gross_profit_margin": 1, "income_tax_expense": 1000, "interest_expense": 243000, "interest_income": 29000, "net_income": -8203000, "period_display_end_date": "Q1, 2018", "period_end_date": "2018-03-31", "period_type": "q1", "pre_tax_profit": -8202000, "revenue": 532000, "total_operating_expense": 8346000 }, { "cost_of_goods_sold": 0, "cost_of_goods_sold_currency": "€", "ebit": -9114000, "ebitda": -9213000, "ebitda_margin": -61.42, "ebit_margin": -60.76, "earnings_per_share": null, "gross_profit": 188000, "gross_profit_margin": 1.2533333333333334, "income_tax_expense": 0, "interest_expense": -243000, "interest_income": 782000, "net_income": -8014000, "period_display_end_date": "Q2, 2018", "period_end_date": "2018-06-30", "period_type": "q2", "pre_tax_profit": -8014000, "revenue": 150000, "total_operating_expense": 9401000 }, { "cost_of_goods_sold": 0, "cost_of_goods_sold_currency": "€", "ebit": -12129000, "ebitda": -12129000, "ebitda_margin": -39.63725490196079, "ebit_margin": -39.63725490196079, "earnings_per_share": null, "gross_profit": 268000, "gross_profit_margin": 0.8758169934640523, "income_tax_expense": 0, "interest_expense": 669000, "interest_income": -687000, "net_income": -12020000, "period_display_end_date": "Q3, 2018", "period_end_date": "2018-09-30", "period_type": "q3", "pre_tax_profit": -12020000, "revenue": 306000, "total_operating_expense": 12397000 }, { "cost_of_goods_sold": 0, "cost_of_goods_sold_currency": "€", "ebit": -19536000, "ebitda": -19185000, "ebitda_margin": -0.8082999789340636, "ebit_margin": -0.8230882662734359, "earnings_per_share": null, "gross_profit": 25250000, "gross_profit_margin": 1.0638297872340425, "income_tax_expense": 1000, "interest_expense": 847000, "interest_income": 256000, "net_income": -19477000, "period_display_end_date": "FY, 2018", "period_end_date": "2018-12-31", "period_type": "fiscal_year", "pre_tax_profit": -19476000, "revenue": 23735000, "total_operating_expense": 44435000 }, { "cost_of_goods_sold": 0, "cost_of_goods_sold_currency": "€", "ebit": 1018000, "ebitda": 1228000, "ebitda_margin": 0.10816524266713644, "ebit_margin": 0.08966792918171408, "earnings_per_share": null, "gross_profit": 11439000, "gross_profit_margin": 1.0075750902845062, "income_tax_expense": 0, "interest_expense": 161000, "interest_income": 995000, "net_income": 1852000, "period_display_end_date": "Q1, 2019", "period_end_date": "2019-03-31", "period_type": "q1", "pre_tax_profit": 1852000, "revenue": 11353000, "total_operating_expense": 10211000 }, { "cost_of_goods_sold": 0, "cost_of_goods_sold_currency": "€", "ebit": -9682000, "ebitda": -9892000, "ebitda_margin": -2.468063872255489, "ebit_margin": -2.415668662674651, "earnings_per_share": null, "gross_profit": 4205000, "gross_profit_margin": 1.0491516966067864, "income_tax_expense": 4000, "interest_expense": 122000, "interest_income": -560000, "net_income": -10340000, "period_display_end_date": "Q2, 2019", "period_end_date": "2019-06-30", "period_type": "q2", "pre_tax_profit": -10336000, "revenue": 4008000, "total_operating_expense": 14097000 }, { "cost_of_goods_sold": 0, "cost_of_goods_sold_currency": "€", "ebit": -12691000, "ebitda": -12691000, "ebitda_margin": -6.03471231573942, "ebit_margin": -6.03471231573942, "earnings_per_share": null, "gross_profit": 1820000, "gross_profit_margin": 0.8654303376129339, "income_tax_expense": 0, "interest_expense": 106000, "interest_income": 488000, "net_income": -10884000, "period_display_end_date": "Q3, 2019", "period_end_date": "2019-09-30", "period_type": "q3", "pre_tax_profit": -10884000, "revenue": 2103000, "total_operating_expense": 14511000 }, { "cost_of_goods_sold": 0, "cost_of_goods_sold_currency": "€", "ebit": -32376000, "ebitda": -31651000, "ebitda_margin": -1.4796409705016127, "ebit_margin": -1.5135337291384228, "earnings_per_share": null, "gross_profit": 21681000, "gross_profit_margin": 1.013557103454724, "income_tax_expense": 4000, "interest_expense": 483000, "interest_income": 602000, "net_income": -32365000, "period_display_end_date": "FY, 2019", "period_end_date": "2019-12-31", "period_type": "fiscal_year", "pre_tax_profit": -32361000, "revenue": 21391000, "total_operating_expense": 53332000 }, { "cost_of_goods_sold": 0, "cost_of_goods_sold_currency": "€", "ebit": -9896000, "ebitda": -9896000, "ebitda_margin": -1.9271665043816943, "ebit_margin": -1.9271665043816943, "earnings_per_share": null, "gross_profit": 5135000, "gross_profit_margin": 1, "income_tax_expense": 0, "interest_expense": 64000, "interest_income": 0, "net_income": -8289000, "period_display_end_date": "Q1, 2020", "period_end_date": "2020-03-31", "period_type": "q1", "pre_tax_profit": -8289000, "revenue": 5135000, "total_operating_expense": 15031000 }, { "cost_of_goods_sold": 0, "cost_of_goods_sold_currency": "€", "ebit": -11284000, "ebitda": -11284000, "ebitda_margin": -3.8459441036128155, "ebit_margin": -3.8459441036128155, "earnings_per_share": null, "gross_profit": 2962000, "gross_profit_margin": 1.009543285616905, "income_tax_expense": 0, "interest_expense": 65000, "interest_income": 0, "net_income": -12238000, "period_display_end_date": "Q2, 2020", "period_end_date": "2020-06-30", "period_type": "q2", "pre_tax_profit": -12238000, "revenue": 2934000, "total_operating_expense": 14246000 }, { "cost_of_goods_sold": 0, "cost_of_goods_sold_currency": "€", "ebit": -2909000, "ebitda": -2909000, "ebitda_margin": -0.27586533902323374, "ebit_margin": -0.27586533902323374, "earnings_per_share": null, "gross_profit": 10647000, "gross_profit_margin": 1.0096728307254623, "income_tax_expense": 0, "interest_expense": 45000, "interest_income": 0, "net_income": -5966000, "period_display_end_date": "Q3, 2020", "period_end_date": "2020-09-30", "period_type": "q3", "pre_tax_profit": -5966000, "revenue": 10545000, "total_operating_expense": 13556000 }, { "cost_of_goods_sold": 0, "cost_of_goods_sold_currency": "€", "ebit": -34718000, "ebitda": -33884000, "ebitda_margin": -1.1947813822284907, "ebit_margin": -1.2241889985895629, "earnings_per_share": null, "gross_profit": 28986000, "gross_profit_margin": 1.0220733427362483, "income_tax_expense": 1000, "interest_expense": 140000, "interest_income": 186000, "net_income": -41366000, "period_display_end_date": "FY, 2020", "period_end_date": "2020-12-31", "period_type": "fiscal_year", "pre_tax_profit": -41365000, "revenue": 28360000, "total_operating_expense": 62870000 }, { "cost_of_goods_sold": 0, "cost_of_goods_sold_currency": "€", "ebit": -4085000, "ebitda": -4085000, "ebitda_margin": -0.3503731023243846, "ebit_margin": -0.3503731023243846, "earnings_per_share": null, "gross_profit": 11806000, "gross_profit_margin": 1.0126082854447207, "income_tax_expense": 2000, "interest_expense": 123000, "interest_income": 0, "net_income": 1412000, "period_display_end_date": "Q1, 2021", "period_end_date": "2021-03-31", "period_type": "q1", "pre_tax_profit": 1414000, "revenue": 11659000, "total_operating_expense": 15891000 }, { "cost_of_goods_sold": 0, "cost_of_goods_sold_currency": "€", "ebit": -17200000, "ebitda": -16576000, "ebitda_margin": -1.7076336664262903, "ebit_margin": -1.771917173173998, "earnings_per_share": null, "gross_profit": 10039000, "gross_profit_margin": 1.0342021221798703, "income_tax_expense": 0, "interest_expense": 343000, "interest_income": 0, "net_income": -18752000, "period_display_end_date": "Q2, 2021", "period_end_date": "2021-06-30", "period_type": "q2", "pre_tax_profit": -18752000, "revenue": 9707000, "total_operating_expense": 26615000 }, { "cost_of_goods_sold": 0, "cost_of_goods_sold_currency": "€", "ebit": -18569000, "ebitda": -19193000, "ebitda_margin": -2.2157700300161625, "ebit_margin": -2.1437312398984067, "earnings_per_share": null, "gross_profit": 8893000, "gross_profit_margin": 1.0266682059570538, "income_tax_expense": 0, "interest_expense": 335000, "interest_income": 0, "net_income": -17095000, "period_display_end_date": "Q3, 2021", "period_end_date": "2021-09-30", "period_type": "q3", "pre_tax_profit": -17095000, "revenue": 8662000, "total_operating_expense": 28086000 }, { "cost_of_goods_sold": 0, "cost_of_goods_sold_currency": "€", "ebit": -64030000, "ebitda": -62697000, "ebitda_margin": -1.553213100133776, "ebit_margin": -1.586235941138582, "earnings_per_share": null, "gross_profit": 41676000, "gross_profit_margin": 1.0324530545508597, "income_tax_expense": 2000, "interest_expense": 1127000, "interest_income": 0, "net_income": -57523000, "period_display_end_date": "FY, 2021", "period_end_date": "2021-12-31", "period_type": "fiscal_year", "pre_tax_profit": -57521000, "revenue": 40366000, "total_operating_expense": 104373000 }, { "cost_of_goods_sold": 0, "cost_of_goods_sold_currency": "€", "ebit": -17134000, "ebitda": -17134000, "ebitda_margin": -2.1401448913315013, "ebit_margin": -2.1401448913315013, "earnings_per_share": null, "gross_profit": 8290000, "gross_profit_margin": 1.0354733949537847, "income_tax_expense": 2000, "interest_expense": 444000, "interest_income": 0, "net_income": -16665000, "period_display_end_date": "Q1, 2022", "period_end_date": "2022-03-31", "period_type": "q1", "pre_tax_profit": -16663000, "revenue": 8006000, "total_operating_expense": 25424000 }, { "cost_of_goods_sold": 0, "cost_of_goods_sold_currency": "€", "ebit": -21662000, "ebitda": -21662000, "ebitda_margin": -2.9669908231749074, "ebit_margin": -2.9669908231749074, "earnings_per_share": null, "gross_profit": 7541000, "gross_profit_margin": 1.0328722092863991, "income_tax_expense": 0, "interest_expense": 400000, "interest_income": 0, "net_income": -19409000, "period_display_end_date": "Q2, 2022", "period_end_date": "2022-06-30", "period_type": "q2", "pre_tax_profit": -19409000, "revenue": 7301000, "total_operating_expense": 29203000 }, { "cost_of_goods_sold": 0, "cost_of_goods_sold_currency": "€", "ebit": -19209000, "ebitda": -19209000, "ebitda_margin": -1.2902337452982269, "ebit_margin": -1.2902337452982269, "earnings_per_share": null, "gross_profit": 15006000, "gross_profit_margin": 1.0079258463191831, "income_tax_expense": 0, "interest_expense": 323000, "interest_income": 0, "net_income": -16490000, "period_display_end_date": "Q3, 2022", "period_end_date": "2022-09-30", "period_type": "q3", "pre_tax_profit": -16490000, "revenue": 14888000, "total_operating_expense": 34215000 }, { "cost_of_goods_sold": 0, "cost_of_goods_sold_currency": "€", "ebit": -88119000, "ebitda": -85219000, "ebitda_margin": -2.060769472589655, "ebit_margin": -2.130897395594032, "earnings_per_share": null, "gross_profit": 42770000, "gross_profit_margin": 1.0342659541024835, "income_tax_expense": 2000, "interest_expense": 1630000, "interest_income": 0, "net_income": -86004000, "period_display_end_date": "FY, 2022", "period_end_date": "2022-12-31", "period_type": "fiscal_year", "pre_tax_profit": -86002000, "revenue": 41353000, "total_operating_expense": 127989000 }, { "cost_of_goods_sold": 0, "cost_of_goods_sold_currency": "€", "ebit": -31461000, "ebitda": -31461000, "ebitda_margin": -6.975831485587583, "ebit_margin": -6.975831485587583, "earnings_per_share": null, "gross_profit": 4920000, "gross_profit_margin": 1.0909090909090908, "income_tax_expense": 3000, "interest_expense": 477000, "interest_income": 0, "net_income": -31983000, "period_display_end_date": "Q1, 2023", "period_end_date": "2023-03-31", "period_type": "q1", "pre_tax_profit": -31980000, "revenue": 4510000, "total_operating_expense": 36381000 }, { "cost_of_goods_sold": 0, "cost_of_goods_sold_currency": "€", "ebit": -29442000, "ebitda": -29442000, "ebitda_margin": -21.181294964028776, "ebit_margin": -21.181294964028776, "earnings_per_share": null, "gross_profit": 2107000, "gross_profit_margin": 1.5158273381294964, "income_tax_expense": 0, "interest_expense": 470000, "interest_income": 0, "net_income": -29395000, "period_display_end_date": "Q2, 2023", "period_end_date": "2023-06-30", "period_type": "q2", "pre_tax_profit": -29395000, "revenue": 1390000, "total_operating_expense": 31549000 }, { "cost_of_goods_sold": 0, "cost_of_goods_sold_currency": "€", "ebit": -24923000, "ebitda": -24923000, "ebitda_margin": -12.702854230377167, "ebit_margin": -12.702854230377167, "earnings_per_share": null, "gross_profit": 1956000, "gross_profit_margin": 0.9969418960244648, "income_tax_expense": 0, "interest_expense": 447000, "interest_income": 138000, "net_income": -24355000, "period_display_end_date": "Q3, 2023", "period_end_date": "2023-09-30", "period_type": "q3", "pre_tax_profit": -24355000, "revenue": 1962000, "total_operating_expense": 26879000 }, { "cost_of_goods_sold": 0, "cost_of_goods_sold_currency": "€", "ebit": -106661000, "ebitda": -104912000, "ebitda_margin": -12.678187311178247, "ebit_margin": -12.889546827794561, "earnings_per_share": null, "gross_profit": 12972000, "gross_profit_margin": 1.5676132930513595, "income_tax_expense": 3000, "interest_expense": 1806000, "interest_income": 509000, "net_income": -105938000, "period_display_end_date": "FY, 2023", "period_end_date": "2023-12-31", "period_type": "fiscal_year", "pre_tax_profit": -105935000, "revenue": 8275000, "total_operating_expense": 117884000 }, { "cost_of_goods_sold": 0, "cost_of_goods_sold_currency": "€", "ebit": -19535000, "ebitda": -19535000, "ebitda_margin": -126.03225806451613, "ebit_margin": -126.03225806451613, "earnings_per_share": null, "gross_profit": 332000, "gross_profit_margin": 2.141935483870968, "income_tax_expense": 0, "interest_expense": 363000, "interest_income": 367000, "net_income": -19175000, "period_display_end_date": "Q1, 2024", "period_end_date": "2024-03-31", "period_type": "q1", "pre_tax_profit": -19175000, "revenue": 155000, "total_operating_expense": 19867000 }, { "cost_of_goods_sold": 0, "cost_of_goods_sold_currency": "€", "ebit": -15553000, "ebitda": -15553000, "ebitda_margin": -100.99350649350649, "ebit_margin": -100.99350649350649, "earnings_per_share": null, "gross_profit": 210000, "gross_profit_margin": 1.3636363636363635, "income_tax_expense": 3000, "interest_expense": 351000, "interest_income": 306000, "net_income": -15451000, "period_display_end_date": "Q2, 2024", "period_end_date": "2024-06-30", "period_type": "q2", "pre_tax_profit": -15448000, "revenue": 154000, "total_operating_expense": 15763000 }, { "cost_of_goods_sold": 0, "cost_of_goods_sold_currency": "€", "ebit": -14283000, "ebitda": -11338000, "ebitda_margin": -73.14838709677419, "ebit_margin": -92.14838709677419, "earnings_per_share": null, "gross_profit": 164000, "gross_profit_margin": 1.0580645161290323, "income_tax_expense": 1000, "interest_expense": 325000, "interest_income": 228000, "net_income": -15139000, "period_display_end_date": "Q3, 2024", "period_end_date": "2024-09-30", "period_type": "q3", "pre_tax_profit": -15138000, "revenue": 155000, "total_operating_expense": 11502000 } ], "stock_information": [ { "closing_price": 2.140000104904175, "currency": "$", "date": "2022-11-30", "marketcap": 256365600 }, { "closing_price": 3.099999904632568, "currency": "$", "date": "2022-05-31", "marketcap": 371370688 }, { "closing_price": 0.597999989986419, "currency": "$", "date": "2023-06-30", "marketcap": 89334600 }, { "closing_price": 6.179999828338623, "currency": "$", "date": "2021-09-30", "marketcap": 735129536 }, { "closing_price": 0.550999999046325, "currency": "$", "date": "2024-01-31", "marketcap": 82285792 }, { "closing_price": 5.91, "currency": "$", "date": "2021-11-12", "marketcap": 576946645 }, { "closing_price": 2.059999942779541, "currency": "$", "date": "2022-09-30", "marketcap": 246781808 }, { "closing_price": 5.52, "currency": "$", "date": "2021-12-31", "marketcap": 559254925 }, { "closing_price": 3.359999895095825, "currency": "$", "date": "2024-09-30", "marketcap": 52687488 }, { "closing_price": 5.449999809265137, "currency": "$", "date": "2024-06-28", "marketcap": 82989872 }, { "closing_price": 0.47799998521804804, "currency": "$", "date": "2023-09-29", "marketcap": 71369112 }, { "closing_price": 5.07, "currency": "$", "date": "2024-07-31", "marketcap": 77203425 }, { "closing_price": 5.300000190734863, "currency": "$", "date": "2024-03-28", "marketcap": 79149672 }, { "closing_price": 3.349999904632568, "currency": "$", "date": "2024-10-29", "marketcap": 52530680 }, { "closing_price": 0.625, "currency": "$", "date": "2023-12-29", "marketcap": 93336880 }, { "closing_price": 4.35, "currency": "$", "date": "2024-05-31", "marketcap": 61823500 }, { "closing_price": 2.769999980926513, "currency": "$", "date": "2022-06-30", "marketcap": 331837696 }, { "closing_price": 0.9089999794960021, "currency": "$", "date": "2023-02-28", "marketcap": 135779024 }, { "closing_price": 0.8999999761581421, "currency": "$", "date": "2023-04-27", "marketcap": 134405104 }, { "closing_price": 5.349999904632568, "currency": "$", "date": "2024-04-30", "marketcap": 81467120 }, { "closing_price": 4.409999847412109, "currency": "$", "date": "2022-02-28", "marketcap": 528304736 }, { "closing_price": 6.800000190734863, "currency": "$", "date": "2021-10-29", "marketcap": 788658432 }, { "closing_price": 0.5899999737739561, "currency": "$", "date": "2023-07-31", "marketcap": 88110008 }, { "closing_price": 2.829999923706054, "currency": "$", "date": "2022-07-29", "marketcap": 339025504 }, { "closing_price": 0.395000010728836, "currency": "$", "date": "2023-10-31", "marketcap": 58988908 }, { "closing_price": 4.230000019073486, "currency": "$", "date": "2024-08-30", "marketcap": 67305224 }, { "closing_price": 4.079999923706055, "currency": "$", "date": "2022-01-31", "marketcap": 488771744 }, { "closing_price": 1.240000009536743, "currency": "$", "date": "2022-12-30", "marketcap": 148548288 }, { "closing_price": 1.759999990463256, "currency": "$", "date": "2022-10-31", "marketcap": 210842720 }, { "closing_price": 0.8799999952316281, "currency": "$", "date": "2023-05-31", "marketcap": 131373528 }, { "closing_price": 0.7459999918937681, "currency": "$", "date": "2023-03-31", "marketcap": 111347160 }, { "closing_price": 4.369999885559082, "currency": "$", "date": "2022-03-31", "marketcap": 523512864 }, { "closing_price": 7.039999961853027, "currency": "$", "date": "2021-08-31", "marketcap": 837429120 }, { "closing_price": 0.44999998807907104, "currency": "$", "date": "2023-11-30", "marketcap": 67202552 }, { "closing_price": 2.619999885559082, "currency": "$", "date": "2022-08-31", "marketcap": 313868128 }, { "closing_price": 0.544000029563903, "currency": "$", "date": "2023-08-31", "marketcap": 81240424 }, { "closing_price": 1.289999961853027, "currency": "$", "date": "2023-01-31", "marketcap": 154538128 }, { "closing_price": 0.601999998092651, "currency": "$", "date": "2024-02-29", "marketcap": 89902080 }, { "closing_price": 3.789999961853027, "currency": "$", "date": "2022-04-27", "marketcap": 454030624 } ], "last_funding_round_name": "Post-IPO Equity - Affimed", "last_funding_round_announced_date": "2022-04-13", "last_funding_round_lead_investors": [], "last_funding_round_amount_raised": 90000000, "last_funding_round_amount_raised_currency": "$", "last_funding_round_num_investors": null, "funding_rounds": [ { "name": "Post-IPO Equity - Affimed", "announced_date": "2022-04-13", "lead_investors": [], "amount_raised": 90000000, "amount_raised_currency": "$", "num_investors": null }, { "name": "Post-IPO Equity - Affimed", "announced_date": "2021-01-12", "lead_investors": [], "amount_raised": 115000000, "amount_raised_currency": "$", "num_investors": null }, { "name": "Post-IPO Debt - Affimed", "announced_date": "2021-01-11", "lead_investors": [ "********" ], "amount_raised": 12160006, "amount_raised_currency": "$", "num_investors": 1 }, { "name": "Post-IPO Equity - Affimed", "announced_date": "2019-11-07", "lead_investors": [], "amount_raised": 34500000, "amount_raised_currency": "$", "num_investors": null }, { "name": "Post-IPO Equity - Affimed", "announced_date": "2018-08-27", "lead_investors": [ "********" ], "amount_raised": 96000000, "amount_raised_currency": "$", "num_investors": 1 }, { "name": "Post-IPO Equity - Affimed", "announced_date": "2017-01-19", "lead_investors": [], "amount_raised": 16600000, "amount_raised_currency": "$", "num_investors": null }, { "name": "Post-IPO Equity - Affimed", "announced_date": "2015-10-01", "lead_investors": [ "********" ], "amount_raised": 21376011, "amount_raised_currency": "$", "num_investors": 1 }, { "name": "Post-IPO Equity - Affimed", "announced_date": "2015-05-04", "lead_investors": [], "amount_raised": 37100000, "amount_raised_currency": "$", "num_investors": null }, { "name": "Grant - Affimed", "announced_date": "2015-01-07", "lead_investors": [ "********" ], "amount_raised": 3000000, "amount_raised_currency": "$", "num_investors": 1 }, { "name": "Debt Financing - Affimed", "announced_date": "2014-09-02", "lead_investors": [ "********" ], "amount_raised": 14000000, "amount_raised_currency": "$", "num_investors": 1 }, { "name": "Series E - Affimed", "announced_date": "2014-09-02", "lead_investors": [ "********" ], "amount_raised": 15700000, "amount_raised_currency": "$", "num_investors": 5 }, { "name": "Series D - Affimed", "announced_date": "2012-10-08", "lead_investors": [ "********" ], "amount_raised": 20101102, "amount_raised_currency": "$", "num_investors": 5 }, { "name": "Series B - Affimed", "announced_date": "2007-04-04", "lead_investors": [ "********", "********", "********" ], "amount_raised": 32000000, "amount_raised_currency": "$", "num_investors": 4 }, { "name": "Grant - Affimed", "announced_date": "2015-01-07", "lead_investors": [ "********" ], "amount_raised": 3000000, "amount_raised_currency": "$", "num_investors": 1 } ], "ownership_status": "Public", "parent_company_information": null, "acquired_by_summary": null, "num_acquisitions_source_1": null, "acquisition_list_source_1": [], "num_acquisitions_source_2": null, "acquisition_list_source_2": [], "num_acquisitions_source_5": null, "acquisition_list_source_5": [], "competitors": [ { "company_name": "juno therapeutics", "similarity_score": 8999 }, { "company_name": "eolo-pharma", "similarity_score": 5263 }, { "company_name": "ose immunotherapeutics", "similarity_score": 6126 }, { "company_name": "carisma", "similarity_score": 7197 }, { "company_name": "array biopharma", "similarity_score": null }, { "company_name": "skyepharma", "similarity_score": null }, { "company_name": "neximmune", "similarity_score": 7008 }, { "company_name": "tcr2", "similarity_score": 8117 }, { "company_name": "fate therapeutics", "similarity_score": 5538 }, { "company_name": "btg", "similarity_score": null }, { "company_name": "tricida", "similarity_score": null }, { "company_name": "allogene", "similarity_score": 10023 }, { "company_name": "gilead", "similarity_score": 5187 }, { "company_name": "morphosys", "similarity_score": 5604 }, { "company_name": "zymeworks", "similarity_score": 7482 }, { "company_name": "medigene", "similarity_score": 94679 }, { "company_name": "aldeyra therapeutics", "similarity_score": 6325 }, { "company_name": "adaptimmune", "similarity_score": 100000 }, { "company_name": "immunocore", "similarity_score": 99497 }, { "company_name": "iovance", "similarity_score": 6059 }, { "company_name": "regeneron", "similarity_score": 5481 }, { "company_name": "immatics", "similarity_score": 11948 }, { "company_name": "noxxon pharma", "similarity_score": 6296 } ], "competitors_websites": [], "company_phone_numbers": [ "********", "********", "********", "********" ], "company_emails": [ "****@affimed.com" ], "pricing_available": 0, "free_trial_available": 0, "demo_available": 0, "is_downloadable": 0, "mobile_apps_exist": 0, "online_reviews_exist": 0, "documentation_exist": 0, "product_reviews_count": null, "product_reviews_aggregate_score": null, "product_reviews_score_distribution": null, "product_pricing_summary": [], "num_news_articles": null, "news_articles": [], "num_technologies_used": 5, "technologies_used": [ { "technology": "gmail", "first_verified_at": "2024-06-10", "last_verified_at": "2024-08-26" }, { "technology": "well", "first_verified_at": "2024-05-20", "last_verified_at": "2025-03-31" }, { "technology": "c", "first_verified_at": "2024-05-20", "last_verified_at": "2025-03-31" }, { "technology": "amp", "first_verified_at": "2024-05-20", "last_verified_at": "2025-03-31" }, { "technology": "impact", "first_verified_at": "2024-04-04", "last_verified_at": "2024-05-13" } ], "total_website_visits_monthly": null, "visits_change_monthly": null, "rank_global": null, "rank_country": null, "rank_category": null, "visits_breakdown_by_country": [], "visits_breakdown_by_gender": null, "visits_breakdown_by_age": null, "bounce_rate": null, "pages_per_visit": null, "average_visit_duration_seconds": null, "similarly_ranked_websites": [], "top_topics": [], "company_employee_reviews_count": null, "company_employee_reviews_aggregate_score": null, "employee_reviews_score_breakdown": null, "employee_reviews_score_distribution": null, "active_job_postings_count": null, "active_job_postings_titles": [], "base_salary": [], "additional_pay": [], "total_salary": [], "employees_count_breakdown_by_seniority": { "employees_count_owner": 0, "employees_count_founder": 0, "employees_count_clevel": 3, "employees_count_partner": 0, "employees_count_vp": 7, "employees_count_head": 2, "employees_count_director": 6, "employees_count_manager": 16, "employees_count_senior": 6, "employees_count_intern": 0, "employees_count_specialist": 16, "employees_count_other_management": 15 }, "employees_count_breakdown_by_department": { "employees_count_medical": 5, "employees_count_sales": 1, "employees_count_hr": 4, "employees_count_legal": 1, "employees_count_marketing": 2, "employees_count_finance": 1, "employees_count_technical": 4, "employees_count_consulting": 0, "employees_count_operations": 7, "employees_count_product": 0, "employees_count_general_management": 9, "employees_count_administrative": 0, "employees_count_customer_service": 0, "employees_count_project_management": 5, "employees_count_design": 0, "employees_count_research": 14, "employees_count_trades": 0, "employees_count_real_estate": 0, "employees_count_education": 0, "employees_count_other_department": 18 }, "employees_count_breakdown_by_region": { "employees_count_eastern_europe": 0, "employees_count_latin_america": 0, "employees_count_southern_europe": 1, "employees_count_sub_saharan_africa": 0, "employees_count_central_asia": 0, "employees_count_northern_america": 8, "employees_count_australia_new_zealand": 0, "employees_count_northern_europe": 1, "employees_count_south_eastern_asia": 0, "employees_count_polynesia": 0, "employees_count_southern_asia": 0, "employees_count_northern_africa": 0, "employees_count_melanesia": 0, "employees_count_western_europe": 61, "employees_count_western_asia": 0, "employees_count_eastern_asia": 0, "employees_count_micronesia": 0, "employees_count_unknown": 0 }, "employees_count_by_country": [ { "country": "United Kingdom", "employee_count": 1 }, { "country": "Switzerland", "employee_count": 2 }, { "country": "United States", "employee_count": 8 }, { "country": "France", "employee_count": 2 }, { "country": "Austria", "employee_count": 2 }, { "country": "Germany", "employee_count": 54 }, { "country": "Netherlands", "employee_count": 1 }, { "country": "Spain", "employee_count": 1 } ], "key_executives": [ { "member_id": 82197925, "member_full_name": "*******", "member_position_title": "Director Procurement" }, { "member_id": 224285965, "member_full_name": "*******", "member_position_title": "CFO" }, { "member_id": 284281141, "member_full_name": "*******", "member_position_title": "Head Of Drug Supply" }, { "member_id": 420952559, "member_full_name": "*******", "member_position_title": "Medical Director" }, { "member_id": 394821732, "member_full_name": "*******", "member_position_title": "Director Commercial Development" }, { "member_id": 65744794, "member_full_name": "*******", "member_position_title": "Head Of Information Security" }, { "member_id": 395148020, "member_full_name": "*******", "member_position_title": "Head Of Marketing And Communications" }, { "member_id": 247160550, "member_full_name": "*******", "member_position_title": "General Counsel" }, { "member_id": 413800944, "member_full_name": "*******", "member_position_title": "Research Associate Translational Immunobiology" }, { "member_id": 340385628, "member_full_name": "*******", "member_position_title": "Principal Statistician And Head Of Programming" }, { "member_id": 341701203, "member_full_name": "*******", "member_position_title": "Chief Medical Officer And Member Of Executive Management Board" }, { "member_id": 424912848, "member_full_name": "*******", "member_position_title": "Quality GMP Manager" }, { "member_id": 613003726, "member_full_name": "*******", "member_position_title": "Medical Director Research And Development" }, { "member_id": 431224317, "member_full_name": "*******", "member_position_title": "Chief Operating And Strategy Officer" }, { "member_id": 540355869, "member_full_name": "*******", "member_position_title": "Vorstand" } ], "key_employee_change_events": [ { "employee_change_event_name": "*******", "employee_change_event_date": "2024-09-03", "employee_change_event_url": null } ], "key_executive_arrivals": [], "key_executive_departures": [ { "member_id": 431224317, "member_full_name": "*******", "member_position_title": "Chief Operating Officer", "departure_date": "Nov 2024" } ], "employees_count_change": { "current": 90, "change_monthly": -1, "change_monthly_percentage": -1.098901098901099, "change_quarterly": -9, "change_quarterly_percentage": -9.090909090909092, "change_yearly": -55, "change_yearly_percentage": -37.93103448275862 }, "employees_count_by_month": [ { "employees_count": 62, "date": "2019-11" }, { "employees_count": 145, "date": "2024-04" }, { "employees_count": 154, "date": "2023-04" }, { "employees_count": 112, "date": "2021-12" }, { "employees_count": 148, "date": "2023-01" }, { "employees_count": 148, "date": "2022-12" }, { "employees_count": 106, "date": "2021-10" }, { "employees_count": 109, "date": "2021-11" }, { "employees_count": 149, "date": "2023-02" }, { "employees_count": 127, "date": "2024-05" }, { "employees_count": 134, "date": "2022-09" }, { "employees_count": 80, "date": "2020-10" }, { "employees_count": 47, "date": "2019-05" }, { "employees_count": 44, "date": "2019-01" }, { "employees_count": 138, "date": "2022-10" }, { "employees_count": 101, "date": "2024-12" }, { "employees_count": 72, "date": "2020-08" }, { "employees_count": 153, "date": "2023-06" }, { "employees_count": 85, "date": "2021-03" }, { "employees_count": 127, "date": "2022-06" }, { "employees_count": 115, "date": "2022-02" }, { "employees_count": 143, "date": "2023-11" }, { "employees_count": 115, "date": "2022-01" }, { "employees_count": 105, "date": "2024-09" }, { "employees_count": 112, "date": "2024-07" }, { "employees_count": 106, "date": "2024-10" }, { "employees_count": 63, "date": "2019-12" }, { "employees_count": 154, "date": "2023-09" }, { "employees_count": 152, "date": "2023-03" }, { "employees_count": 139, "date": "2024-02" }, { "employees_count": 66, "date": "2020-03" }, { "employees_count": 141, "date": "2022-11" }, { "employees_count": 98, "date": "2025-02" }, { "employees_count": 120, "date": "2022-04" }, { "employees_count": 119, "date": "2024-06" }, { "employees_count": 78, "date": "2020-12" }, { "employees_count": 92, "date": "2021-06" }, { "employees_count": 117, "date": "2022-03" }, { "employees_count": 47, "date": "2019-03" }, { "employees_count": 80, "date": "2020-11" }, { "employees_count": 99, "date": "2025-01" }, { "employees_count": 145, "date": "2024-03" }, { "employees_count": 82, "date": "2021-02" }, { "employees_count": 91, "date": "2025-03" }, { "employees_count": 139, "date": "2023-12" }, { "employees_count": 110, "date": "2024-08" }, { "employees_count": 78, "date": "2020-09" }, { "employees_count": 57, "date": "2019-10" }, { "employees_count": 102, "date": "2021-09" }, { "employees_count": 47, "date": "2019-04" }, { "employees_count": 67, "date": "2020-07" }, { "employees_count": 131, "date": "2022-07" }, { "employees_count": 57, "date": "2019-09" }, { "employees_count": 154, "date": "2023-05" }, { "employees_count": 69, "date": "2020-05" }, { "employees_count": 60, "date": "2020-02" }, { "employees_count": 66, "date": "2020-06" }, { "employees_count": 88, "date": "2021-04" }, { "employees_count": 90, "date": "2021-05" }, { "employees_count": 53, "date": "2019-06" }, { "employees_count": 141, "date": "2024-01" }, { "employees_count": 62, "date": "2020-01" }, { "employees_count": 155, "date": "2023-08" }, { "employees_count": 104, "date": "2024-11" }, { "employees_count": 159, "date": "2023-07" }, { "employees_count": 53, "date": "2019-07" }, { "employees_count": 90, "date": "2025-04" }, { "employees_count": 130, "date": "2022-08" }, { "employees_count": 65, "date": "2020-04" }, { "employees_count": 97, "date": "2021-07" }, { "employees_count": 148, "date": "2023-10" }, { "employees_count": 44, "date": "2019-02" }, { "employees_count": 122, "date": "2022-05" }, { "employees_count": 79, "date": "2021-01" }, { "employees_count": 57, "date": "2019-08" }, { "employees_count": 99, "date": "2021-08" } ], "professional_network_followers_count_change": { "current": 6779, "change_monthly": 11, "change_monthly_percentage": 0.16252955082742315, "change_quarterly": 182, "change_quarterly_percentage": 2.758829771108079, "change_yearly": 911, "change_yearly_percentage": 15.524880708929789 }, "professional_network_followers_count_by_month": [ { "follower_count": 3719, "date": "2022-08" }, { "follower_count": 5868, "date": "2024-04" }, { "follower_count": 1175, "date": "2020-04" }, { "follower_count": 2853, "date": "2021-12" }, { "follower_count": 4337, "date": "2023-01" }, { "follower_count": 4187, "date": "2022-12" }, { "follower_count": 2594, "date": "2021-10" }, { "follower_count": 2653, "date": "2021-11" }, { "follower_count": 4380, "date": "2023-02" }, { "follower_count": 1409, "date": "2020-07" }, { "follower_count": 3614, "date": "2022-07" }, { "follower_count": 6476, "date": "2024-10" }, { "follower_count": 5474, "date": "2024-01" }, { "follower_count": 2482, "date": "2021-08" }, { "follower_count": 1031, "date": "2020-01" }, { "follower_count": 887, "date": "2019-09" }, { "follower_count": 5028, "date": "2023-08" }, { "follower_count": 5996, "date": "2024-05" }, { "follower_count": 6683, "date": "2025-02" }, { "follower_count": 6501, "date": "2024-11" }, { "follower_count": 744, "date": "2019-05" }, { "follower_count": 2070, "date": "2021-03" }, { "follower_count": 959, "date": "2019-11" }, { "follower_count": 4593, "date": "2023-04" }, { "follower_count": 5081, "date": "2023-09" }, { "follower_count": 1400, "date": "2020-06" }, { "follower_count": 2186, "date": "2021-04" }, { "follower_count": 2285, "date": "2021-05" }, { "follower_count": 813, "date": "2019-06" }, { "follower_count": 1624, "date": "2020-10" }, { "follower_count": 6545, "date": "2024-12" }, { "follower_count": 5337, "date": "2023-11" }, { "follower_count": 4538, "date": "2023-03" }, { "follower_count": 5574, "date": "2024-02" }, { "follower_count": 2419, "date": "2021-07" }, { "follower_count": 5168, "date": "2023-10" }, { "follower_count": 664, "date": "2019-02" }, { "follower_count": 3290, "date": "2022-05" }, { "follower_count": 1827, "date": "2021-01" }, { "follower_count": 4811, "date": "2023-06" }, { "follower_count": 3502, "date": "2022-06" }, { "follower_count": 2979, "date": "2022-02" }, { "follower_count": 2941, "date": "2022-01" }, { "follower_count": 6425, "date": "2024-09" }, { "follower_count": 838, "date": "2019-07" }, { "follower_count": 3204, "date": "2022-04" }, { "follower_count": 6049, "date": "2024-06" }, { "follower_count": 1787, "date": "2020-12" }, { "follower_count": 2323, "date": "2021-06" }, { "follower_count": 3110, "date": "2022-03" }, { "follower_count": 4750, "date": "2023-05" }, { "follower_count": 1315, "date": "2020-05" }, { "follower_count": 1058, "date": "2020-02" }, { "follower_count": 4932, "date": "2023-07" }, { "follower_count": 1514, "date": "2020-08" }, { "follower_count": 887, "date": "2019-08" }, { "follower_count": 723, "date": "2019-03" }, { "follower_count": 1706, "date": "2020-11" }, { "follower_count": 6597, "date": "2025-01" }, { "follower_count": 5732, "date": "2024-03" }, { "follower_count": 3769, "date": "2022-09" }, { "follower_count": 664, "date": "2019-01" }, { "follower_count": 3884, "date": "2022-10" }, { "follower_count": 6174, "date": "2024-07" }, { "follower_count": 995, "date": "2019-12" }, { "follower_count": 1922, "date": "2021-02" }, { "follower_count": 6768, "date": "2025-03" }, { "follower_count": 1118, "date": "2020-03" }, { "follower_count": 3946, "date": "2022-11" }, { "follower_count": 5394, "date": "2023-12" }, { "follower_count": 6255, "date": "2024-08" }, { "follower_count": 1591, "date": "2020-09" }, { "follower_count": 887, "date": "2019-10" }, { "follower_count": 2550, "date": "2021-09" }, { "follower_count": 744, "date": "2019-04" }, { "follower_count": 6779, "date": "2025-04" } ], "active_job_postings_count_change": null, "product_reviews_score_change": null, "product_reviews_score_by_month": [], "total_website_visits_change": null, "total_website_visits_by_month": [], "employee_reviews_score_aggregated_change": null, "employee_reviews_score_aggregated_by_month": [], "employee_reviews_score_business_outlook_change": null, "employee_reviews_score_business_outlook_by_month": [], "employee_reviews_score_career_opportunities_change": null, "employee_reviews_score_career_opportunities_by_month": [], "employee_reviews_score_ceo_approval_change": null, "employee_reviews_score_ceo_approval_by_month": [], "employee_reviews_score_compensation_benefits_change": null, "employee_reviews_score_compensation_benefits_by_month": [], "employee_reviews_score_culture_values_change": null, "employee_reviews_score_culture_values_by_month": [], "employee_reviews_score_diversity_inclusion_change": null, "employee_reviews_score_diversity_inclusion_by_month": [], "employee_reviews_score_recommend_change": null, "employee_reviews_score_recommend_by_month": [], "employee_reviews_score_senior_management_change": null, "employee_reviews_score_senior_management_by_month": [], "employee_reviews_score_work_life_balance_change": null, "employee_reviews_score_work_life_balance_by_month": [], "expired_domain": 0, "unique_domain": 1, "unique_website": 1, "last_updated_at": "2025-04-04", "created_at": "2016-06-25", "industry_group_1": "Biotech", "industry_group_2": null }
Your data must have high quality if you want to turn it into valuable insights. Arm yourself with the latest intel that will paint the big picture about emerging Biotech industry trends and tell you granular, company-level stories.
Each Botswana Biotech company profile, collected and enriched by Coresignal, includes:
Combined, these data points create the most comprehensive Biotech companies in Botswana database. With 500+ data points for analysis, you can be sure to find the answer to any question about the industry.
Access data as comprehensive dataset files or via an API
Boost your existing dataset with the no-code data enrichment tool
Find competitors and similar companies
Track headcount changes
Review Botswana historical company data
200 free collect and 400 search credits
Unlock the Botswana Biotech sector with Coresignal's extensive datasets and data APIs
With over 11 company profiles, you can easily access detailed information to analyze the market, conduct competitive analysis, and qualify sales leads.
You can purchase our data directly through our self-service platform, or integrate it seamlessly into your systems via data APIs. Whether you need a one-time dataset or continuous access, Coresignal offers flexible solutions to meet your needs.
Coresignal is a public web data vendor that delivers fresh data about companies, professionals, and jobs for 500+ leading companies in market research, venture capital investment, HR tech, sales, and marketing industries. Founded in 2016, the company is known for its high-quality, fresh data and professional service. Coresignal is a member of the Ethical Web Data Collection Initiative and supports academic institutions with data for research.
in the market
clients
data records